| Drug ID: | Drug163 |
|---|---|
| Drug Name: | Omilancor |
| CID: | 121299620 |
| DrugBank ID: | DB19277 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT03861143 |
| Molecular Formula: | C30H24N8O2 |
| Molecular Weight: | 528.6 g/mol |
| Isomeric SMILES: | C1CN(CCN1C(=O)C2=CC=CC(=N2)C3=NC4=CC=CC=C4N3)C(=O)C5=CC=CC(=N5)C6=NC7=CC=CC=C7N6 |
| Synonyms: | BT-11; OMILANCOR; A4Y49H6YY8; OMILANCOR [INN]; [4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1H-benzimidazol-2-yl)pyridin-2-yl]methanone; UNII-A4Y49H6YY8; Example 1 [US9556146B2]; Example 1 (US9556146B2); (4-(6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl)piperazin-1-yl)-(6-(1H-benzimidazol-2-yl)pyridin-2-yl)methanone; 1912399-75-7 |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03861143 | Efficacy and Safety of Oral BT-11 in Ulcerative Colitis | PHASE2 | COMPLETED | NImmune Biopharma | Ulcerative Colitis | DRUG: BT-11 (440 mg)|DRUG: BT-11 (880 mg)|DRUG: P… | Details |
| ISRCTN14296856 | A randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of oral BT-11 in mild to moderate ulcerative colitis | PHASE2 | Recruiting | Landos Biopharma Inc. | Ulcerative colitis Digestive System Ulcerative … | A total of 195 subjects with mild to moderate UC … | Details |
| ACTRN12618001210268 | A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers | PHASE1 | Recruiting | Landos Biopharma Australia Pty Ltd | Inflammatory Bowel Disease;Ulcerative colitis;Cro… | For single ascending dose, five dose target range… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During …
PMID: 37436905
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Clostridioides difficile infection (CDI) is an opportunistic infection of the gastrointestinal tract, commonly associated with antibiotic…
WITHDRAWN: EFFICACY, SAFETY, AND TOLERABILITY OF OMILANCOR IN A PHASE 2 RANDOMI…
PMID: 35104848
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Omilancor is an oral, once-daily, gut-restricted, small molecule, first-in-class therapeutic for Crohn's disease (CD) and ulcerative coli…